RadNet completes €91M deal to purchase iCAD
RadNet aims to broaden its breast imaging AI offerings with the acquisition of iCAD.
Related Articles
Thoughtful.ai Announces Growth Investment from New Mountain Capital
Thoughtful Automation Inc. (“Thoughtful.ai”), a leading artificial intelligence (AI)-powered revenue cycle automation company, today announced a strategic in…
How health systems are tackling the rise of ‘shadow AI’ – Becker’s Hospital Review | Healthcare News & Analysis
Shadow AI—the use of unauthorized or unmonitored AI tools within organizations—is an escalating concern, particularly in sectors like healthcare where data privacy and compliance are…
KLAS: Global Healthcare IT Investments and Trends for 2025
A recent report by KLAS Research highlights the key trends shaping healthcare IT investments across the globe in 2025.
Siemens Healthineers to expand product line in China
Siemens Healthineers is to launch about 20 “made-in-China” products in the 2025 fiscal year, according to a report in China Daily.
Precision Neuroscience wins FDA clearance for BCI cortical interface
Precision Neuroscience announced today that it received FDA 510(k) clearance for its Layer 7 cortical interface for BCI technology.
Illumina, Tempus AI partner to drive genomic testing beyond cancer
The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.
Adagio Medical wins FDA breakthrough nod for cryoablation tech
Adagio Medical (Nasdaq:ADGM) announced today that it received FDA breakthrough device designation for its vCLAS cryoablation system.
Sanoculis wins CE mark for minimally invasive glaucoma treatment device
Sanoculis announced that it received CE mark for its MINT (minimally invasive nasal trabeculostomy) product.
Patient privacy amid the rise of AI: 5 notes – Becker’s ASC
While healthcare data breaches fell slightly in 2024 compared to 2023, the number of individuals affected by data breaches sky-rocketed, driven by the February 2024…
Exclusive | Drug Development Is Slowing Down After Cuts at the FDA
The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.